Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

GSVA: gene set variation analysis for microarray and RNA-Seq data

Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440

Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists

Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn923 · Cited by 14,108

TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions.

Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks

Trapnell, C., Roberts, A., Goff, L. A., Pertea, G. M., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. S. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,145

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377

Comprehensive molecular characterization of human colon and rectal cancer

The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499

Cancer immunotherapy using checkpoint blockade

Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645

The Immune Landscape of Cancer

Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

Jiang, P., Gu, S., Pan, D., Fu, J., Sahu, A., Hu, X., Li, Z., Traugh, N., Bu, X., Li, B., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0136-1 · Cited by 5,179

Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade

Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients

Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

Chan, T. A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S. A., Stenzinger, A., & Peters, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy495 · Cited by 2,683

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi, F. S., Martín-Algarra, S., Mandal, R., Sharfman, W. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.028 · Cited by 2,401

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0386 · Cited by 2,264

The immune contexture in cancer prognosis and treatment

Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263

Top 10 Challenges in Cancer Immunotherapy

Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238

Regulation and Function of the PD-L1 Checkpoint

Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,248

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053

The diverse functions of the PD1 inhibitory pathway

Sharpe, A. H., & Pauken, K. E. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.108 · Cited by 2,054

Cancer immunoediting and resistance to T cell-based immunotherapy

O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,826

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

Kim, S. T., Cristescu, R., Bass, A. J., Kim, K., Odegaard, J. I., Kim, K., Liu, X. Q., Sher, X., Jung, H., Lee, M.-J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0101-z · Cited by 1,680

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635

Tumour-intrinsic resistance to immune checkpoint blockade

Kalbasi, A. K., & Ribas, A. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,525

Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy

Spranger, S., Dai, D., Horton, B., & Gajewski, T. F. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.003 · Cited by 1,441

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

Jerby-Arnon, L., Shah, P., Cuoco, M. S., Rodman, C., Su, M.-J., Melms, J. C., Leeson, R., Kanodia, A., Mei, S., Lin, J.-R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.006 · Cited by 1,429

Mechanisms of resistance to immune checkpoint inhibitors

Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337

Conserved pan-cancer microenvironment subtypes predict response to immunotherapy

Bagaev, A., Kotlov, N., Nomie, K., Svekolkin, V., Gafurov, A., Isaeva, O., Osokin, N., Kozlov, I., Frenkel, F., Gancharova, O., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.014 · Cited by 1,302

Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade

Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

Gong, J., Chehrazi‐Raffle, A., Reddi, S., & Salgia, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0316-z · Cited by 1,307

Targeted agents and immunotherapies: optimizing outcomes in melanoma

Luke, J. J., Flaherty, K. T., Ribas, A., & Long, G. V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.43 · Cited by 1,269

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study

Sun, R., Limkin, E. J., Vakalopoulou, M., Dercle, L., Champiat, S., Han, S. R., Verlingue, L., Brandao, D., Lancia, A., Ammari, S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30413-3 · Cited by 1,236

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.022 · Cited by 1,216

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker

Jardim, D. L., Goodman, A., de Melo Gagliato, D., & Kurzrock, R. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.10.001 · Cited by 1,192

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142

Large-scale public data reuse to model immunotherapy response and resistance

Fu, J., Li, K., Zhang, W., Wan, C., Zhang, J., Jiang, P., & Liu, X. S. (2020) · Genome Medicine · doi:10.1186/s13073-020-0721-z · Cited by 1,070

An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma

Sahin, U., Oehm, P., Derhovanessian, E., Jabulowsky, R. A., Vormehr, M., Gold, M., Maurus, D., Schwarck-Kokarakis, D., Kuhn, A. N., Omokoko, T., et al. (2020) · Nature · doi:10.1038/s41586-020-2537-9 · Cited by 1,052

Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells

Klemm, F., Maas, R. R., Bowman, R. L., Kornete, M., Soukup, K., Nassiri, S., Brouland, J., Iacobuzio–Donahue, C. A., Brennan, C., Tabar, V. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.007 · Cited by 1,030

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

Gide, T. N., Quek, C., Menzies, A. M., Tasker, A. T., Shang, P., Holst, J., Madore, J., Lim, S. Y., Velickovic, R., Wongchenko, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.003 · Cited by 1,047

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

McGrail, D. J., Pilié, P. G., Rashid, N. U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E. W., Khasraw, M., Heimberger, A. B., Lim, B., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.006 · Cited by 1,051

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

Liu, D., Schilling, B., Liu, D., Sucker, A., Livingstone, E., Jerby-Arnon, L., Zimmer, L., Gutzmer, R., Satzger, I., Loquai, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0654-5 · Cited by 1,039

CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability

Ma, X., Xiao, L., Liu, L., Ye, L., Pan, S., Bi, E., Wang, Q., Yang, M., Qian, J., & Yi, Q. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.02.015 · Cited by 1,048

Advances in the development of personalized neoantigen-based therapeutic cancer vaccines

Blass, E., & Ott, P. A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00460-2 · Cited by 1,042

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S. L., Hammond, M. R., Vitzthum, H., Blackmon, S. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01062-w · Cited by 1,005

Targeting neoantigens to augment antitumour immunity

Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

Chen, P.-L., Roh, W., Reuben, A., Cooper, Z. A., Spencer, C. N., Prieto, P. A., Miller, J. P., Bassett, R. L., Gopalakrishnan, V., Wani, K., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1545 · Cited by 988

Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures

Zeng, D., Li, M., Zhou, R., Zhang, J., Sun, H., Shi, M., Bin, J., Liao, Y., Rao, J., & Liao, W. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0436 · Cited by 986

ImmuCellAI: A Unique Method for Comprehensive T‐Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy

Miao, Y., Zhang, Q., Lei, Q., Luo, M., Xie, G., Wang, H., & Guo, A. (2020) · Advanced Science · doi:10.1002/advs.201902880 · Cited by 967

Acquired Resistance to Immune Checkpoint Inhibitors

Schoenfeld, A. J., & Hellmann, M. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.017 · Cited by 991

Prospects for combining targeted and conventional cancer therapy with immunotherapy

Gotwals, P. J., Cameron, S. B., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., Mueller, B., Quaratino, S., Sabatos-Peyton, C. A., Petruzzelli, L., et al. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.17 · Cited by 968

A conserved dendritic-cell regulatory program limits antitumour immunity

Maier, B. B., Leader, A. M., Chen, S. T., Tung, N., Chang, C., Bérichel, J. L., Chudnovskiy, A., Maskey, S., Walker, L. A., Finnigan, J. P., et al. (2020) · Nature · doi:10.1038/s41586-020-2134-y · Cited by 939

Neoantigen-directed immune escape in lung cancer evolution

The TRACERx consortium, Rosenthal, R., Cadieux, E. L., Salgado, R., Bakir, M. A., Moore, D. A., Hiley, C. T., Lund, T., Tanić, M., Reading, J. L., et al. (2019) · Nature · doi:10.1038/s41586-019-1032-7 · Cited by 946

TGFβ biology in cancer progression and immunotherapy

Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944

m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer

Zhang, B., Wu, Q., Li, B., Wang, D., Wang, L., & Zhou, Y. L. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01170-0 · Cited by 940

Dendritic cell-based immunotherapy

Sabado, R. L., Balan, S., & Bhardwaj, N. (2016) · Cell Research · doi:10.1038/cr.2016.157 · Cited by 942

Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment

Peranzoni, E., Lemoine, J., Vimeux, L., Feuillet, V., Ghamry-Barrin, S., Kantari‐Mimoun, C., Bercovici, N., Guérin, M. V., Biton, J., Ouakrim, H., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720948115 · Cited by 941

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

Turajlic, S., Litchfield, K., Xu, H., Rosenthal, R., McGranahan, N., Reading, J. L., Wong, Y. N. S., Rowan, A., Kanu, N., Bakir, M. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30516-8 · Cited by 967

Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer.

Kieffer, Y., Hocine, H. R., Gentric, G., Pelon, F., Bernard, C., Bourachot, B., Lameiras, S., Albergante, L., Bonneau, C., Guyard, A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1384 · Cited by 910

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

Zhao, J., Chen, A. X., Gartrell, R. D., Silverman, A. M., Aparicio, L., Chu, T., Bordbar, D., Shan, D., Samanamud, J., Mahajan, A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0349-y · Cited by 903

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer

Anagnostou, V., Smith, K. N., Forde, P. M., Niknafs, N., Bhattacharya, R., White, J. R., Zhang, T., Adleff, V., Phallen, J. A., Wali, N., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0828 · Cited by 918

Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition

Litchfield, K., Reading, J. L., Puttick, C., Thakkar, K., Abbosh, C., Bentham, R., Watkins, T. B. K., Rosenthal, R., Biswas, D., Rowan, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.002 · Cited by 893

Identification of essential genes for cancer immunotherapy

Patel, S. J., Sanjana, N. E., Kishton, R. J., Eidizadeh, A., Vodnala, S. K., Cam, M., Gartner, J. J., Jia, L., Steinberg, S. M., Yamamoto, T. N., et al. (2017) · Nature · doi:10.1038/nature23477 · Cited by 870

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance

Roh, W., Chen, P.-L., Reuben, A., Spencer, C. N., Prieto, P. A., Miller, J. P., Gopalakrishnan, V., Wang, F., Cooper, Z. A., Reddy, S. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah3560 · Cited by 859

MHC-II neoantigens shape tumour immunity and response to immunotherapy

Alspach, E., Lussier, D. M., Miceli, A. P., Kizhvatov, I., DuPage, M., Luoma, A. M., Meng, W., Lichti, C. F., Esaulova, E., Vomund, A. N., et al. (2019) · Nature · doi:10.1038/s41586-019-1671-8 · Cited by 846

Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance

Wu, W. E., Klockow, J., Zhang, M., Lafortune, F., Chang, E., Jin, L., Wu, Y., & Daldrup-Link, H. E. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105780 · Cited by 877

Dynamic EMT: a multi‐tool for tumor progression

Brabletz, S., Schuhwerk, H., Brabletz, T., & Stemmler, M. P. (2021) · The EMBO Journal · doi:10.15252/embj.2021108647 · Cited by 800

Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma

Auslander, N., Zhang, G., Lee, J. S., Frederick, D. T., Miao, B., Moll, T. O. C., Tian, T., Wei, Z., Madan, S., Sullivan, R. J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0157-9 · Cited by 756

Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study

Necchi, A., Anichini, A., Raggi, D., Briganti, A., Massa, S., Lucianò, R., Colecchia, M., Giannatempo, P., Mortarini, R., Bianchi, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01148 · Cited by 741

The clinical role of the TME in solid cancer

Giraldo, N. A., Sánchez-Salas, R., Peske, J. D., Vano, Y. A., Becht, É., Petitprez, F., Validire, P., Ingels, A., Cathelineau, X., Fridman, W. H., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0327-z · Cited by 756

De-novo and acquired resistance to immune checkpoint targeting

Syn, N. L., Teng, M. W. L., Mok, T. S. K., & Soo, R. A. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30607-1 · Cited by 662

DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells

Sato, H., Niimi, A., Yasuhara, T., Permata, T. B. M., Hagiwara, Y., Isono, M., Nuryadi, E., Sekine, R., Oike, T., Kakoti, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01883-9 · Cited by 723

Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies

Anderson, K. G., Stromnes, I. M., & Greenberg, P. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.008 · Cited by 706

TIP: A Web Server for Resolving Tumor Immunophenotype Profiling

Xu, L., Deng, C., Pang, B., Zhang, X., Liu, W., Liao, G., Yuan, H., Peng, C., Li, F., Long, Z., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0689 · Cited by 700

Turning the corner on therapeutic cancer vaccines

Hollingsworth, R. E., & Jansen, K. (2019) · npj Vaccines · doi:10.1038/s41541-019-0103-y · Cited by 689

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment

Passaro, A., Bakir, M. A., Hamilton, E. G., Diehn, M., André, F., Roy‐Chowdhuri, S., Mountzios, G., Wistuba, I. I., Swanton, C., & Peters, S. (2024) · Cell · doi:10.1016/j.cell.2024.02.041 · Cited by 726

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

Zhao, P., Li, L., Jiang, X., & Li, Q. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0738-1 · Cited by 682

Impact of oncogenic pathways on evasion of antitumour immune responses

Spranger, S., & Gajewski, T. F. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.117 · Cited by 675

In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy

Arlauckas, S. P., Garris, C. S., Kohler, R. H., Kitaoka, M., Cuccarese, M. F., Yang, K. S., Miller, M. A., Carlson, J. C., Freeman, G. J., Anthony, R. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3604 · Cited by 669

TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure

Chakravarthy, A., Khan, L., Bensler, N. P., Bose, P., & De Carvalho, D. D. (2018) · Nature Communications · doi:10.1038/s41467-018-06654-8 · Cited by 656

Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?

Fares, C. M., Allen, E. M. V., Drake, C. G., Allison, J. P., & Hu‐Lieskovan, S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_240837 · Cited by 665

Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)

Kim, J. M., & Chen, D. S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw217 · Cited by 648

DNA Damage and Repair Biomarkers of Immunotherapy Response

Mouw, K. W., Goldberg, M. S., Konstantinopoulos, P. A., & D’Andrea, A. D. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0226 · Cited by 664

Cancer immunotherapies targeting the PD-1 signaling pathway

Iwai, Y., Hamanishi, J., Chamoto, K., & Honjo, T. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0329-9 · Cited by 656

Improving cancer immunotherapy through nanotechnology

Goldberg, M. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0186-9 · Cited by 628

Classification of triple-negative breast cancers based on Immunogenomic profiling

He, Y., Jiang, Z., Chen, C., & Wang, X. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-1002-1 · Cited by 633

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors

Miao, D., Margolis, C. A., Vokes, N. I., Liu, D., Taylor-Weiner, A., Wankowicz, S. M., Adeegbe, D., Keliher, D., Schilling, B., Tracy, A., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0200-2 · Cited by 620

Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade

Lu, S., Stein, J. E., Rimm, D. L., Wang, D. W., Bell, M. A., Johnson, D. B., Sosman, J. A., Schalper, K. A., Anders, R. A., Wang, H., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1549 · Cited by 632

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

Jenkins, R. W., Aref, A. R., Lizotte, P. H., Ivanova, E., Stinson, S., Zhou, C. W., Bowden, M., Deng, J., Liu, H., Miao, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0833 · Cited by 594

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592

Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape

Wellenstein, M. D., & de Visser, K. E. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.004 · Cited by 592

ALKBH5 regulates anti–PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment

Li, N., Kang, Y., Wang, L., Huff, S. E., Tang, R., Hui, H., Agrawal, K., Gonzalez, G. M., Wang, Y., Patel, S. P., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1918986117 · Cited by 578

Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies

Patel, S. A., & Minn, A. J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.007 · Cited by 587

A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance

Huang, A. C. C., & Zappasodi, R. (2022) · Nature Immunology · doi:10.1038/s41590-022-01141-1 · Cited by 586

Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors

Heinhuis, K. M., Ros, W., Kok, M., Steeghs, N., Beijnen, J. H., & Schellens, J. H. M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy551 · Cited by 563

CD4 and CD8 T lymphocyte interplay in controlling tumor growth

Ostroumov, D., Fekete-Drimusz, N., Saborowski, M., Kühnel, F., & Woller, N. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2686-7 · Cited by 566

Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers

Teo, M. Y., Seier, K., Ostrovnaya, I., Regazzi, A. M., Kania, B. E., Moran, M. M., Cipolla, C. K., Bluth, M. J., Chaim, J., Al-Ahmadie, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.7740 · Cited by 544

Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade

Benci, J. L., Johnson, L. R., Choa, R., Xu, Y., Qiu, J., Zhou, Z., Xu, B., Ye, D., Nathanson, K. L., June, C. H., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.019 · Cited by 541

Identification of neoantigens for individualized therapeutic cancer vaccines

Lang, F., Schrörs, B., Löwer, M., Türeci, Ö., & Şahin, U. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00387-y · Cited by 569

Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine

Campesato, L. F., Budhu, S., Tchaicha, J. H., Weng, C., Gigoux, M., Cohen, I., Redmond, D., Mangarin, L. M. B., Pourpe, S., Liu, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17750-z · Cited by 549

Transcriptomic and immunophenotypic profiles of melanoma tissue from patients (pts) treated with anti-PD-1 +/- ipilimumab to define mechanisms of response and resistance.

Gide, T. N., Quek, C. Y. J., Menzies, A. M., Madore, J., Velickovic, R., Wongchenko, M. J., Yan, Y., Carlino, M. S., Guminski, A. D., Saw, R. P. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9518

Identification of Features of Response and Resistance to Anti-Programmed-Death-1 Immunotherapy in Melanoma

Zaretsky, J. M. (2017) · eScholarship (California Digital Library)

Transcriptomic Dichotomy in Melanoma: Proliferative Cell Cycle Shield vs. Autoimmune-like Chromatin Activation in Anti-PD-1 ResponsePreprint

Shabana, B., Salem, A., Ramadan, N. A., & Khedr, A. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.09.653199 · Cited by 1

Poster child: Ready for a close-up

Gill, S. I. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6931

Abstract NG04: Mechanisms of resistance to anti-PD-1 immunotherapy through interferon pathway mutations

Zaretsky, J. M., García-Díaz, Á., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu‐Lieskovan, S., Eroglu, Z., Torrejon, D. Y., Tumeh, P. C., Lo, R. S., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ng04 · Cited by 4